Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study - Brana, I; Calles, A; LoRusso, P M (Target Oncol, 2015)